Myomo, INC 8-K filings

Myomo, Inc. filed an amendment to its Form 8-K to correct exhibit labeling and confirm shareholder approvals for director elections, executive compensation, auditor ratification, stock plan amendments, and charter changes.

Myomo stockholders approved an increase in authorized common stock to 100 million shares and expanded the 2018 equity incentive plan.

Myomo, Inc. announced the appointment of Joseph M. Manko Jr. to its Board of Directors, effective May 9, 2026, bringing extensive experience in investment banking and corporate governance.

Myomo, Inc. has appointed healthcare and capital markets veteran William J. Febbo to its Board of Directors to support strategic scaling and investor relations.

Myomo's CEO and CFO voluntarily reduced their 2026 base salaries by 10% in exchange for restricted stock units valued at 115% of the foregone amount.

Myomo, Inc. announced a new $17.5 million debt facility and reported third-quarter 2025 financial results, showing revenue growth but increased net losses and a decline in gross margin.

Myomo, Inc. reported a 28% increase in second-quarter revenue to $9.7 million but significantly lowered its full-year 2025 revenue guidance due to challenges in lead quality and pipeline conversion.

Myomo, Inc. hosted an Investor & Analyst Day to detail its business model, long-term financial aspirations, and product roadmap, targeting $100 million in annual revenue by 2028.

Myomo, Inc. announced the successful approval of Heather Getz as a Class II director and the ratification of CBIZ CPAs P.C. as its independent auditor at its Annual Meeting of Stockholders held on June 11, 2025.

Myomo, Inc. announced a significant revenue increase of 162% in Q1 2025, reaching $9.8 million, fueled by growing adoption of its MyoPro devices.

Myomo, Inc. announces the resignation of two board members and the engagement of a new independent registered public accounting firm following an acquisition.

Myomo, Inc. announces record revenue of $12.1 million and its first-ever positive quarterly cash flow from operations in Q4 2024, along with a revenue guidance of $50 million to $53 million for 2025.

Myomo, Inc. has entered into an amendment to its loan agreement with Silicon Valley Bank, securing a new term loan facility of up to $3 million to bolster its financial position.

Myomo, a wearable medical robotics company, has announced a public offering of common stock to raise approximately $15 million for growth initiatives and product development.

Myomo announced record third-quarter revenue of $9.2 million, an 81% increase year-over-year, and raised its full-year revenue guidance to $30-31 million.

Myomo, Inc. has entered into a lease for a new 36,208 square foot facility in Burlington, MA, to serve as its corporate headquarters and manufacturing site.

Myomo reports record revenue of $7.5 million and a 70% increase in orders and authorizations for its MyoPro devices in the second quarter of 2024.

Myomo, Inc. has entered into a loan agreement with Silicon Valley Bank for a revolving line of credit up to $4 million, potentially increasing to $5.5 million, to support working capital and general business needs.

Myomo reports record preliminary second-quarter revenues of $7.2 million to $7.4 million, significantly exceeding previous expectations and marking a substantial increase from the first quarter.

Myomo, Inc. held its annual meeting on June 5, 2024, where stockholders elected two Class I directors and ratified the appointment of Marcum LLP as the company's independent auditor.

Myomo announced a 9% increase in revenue to $3.8 million for the first quarter of 2024, alongside record growth in patient backlog and pipeline.

Myomo has received its first lump sum reimbursements from Medicare for its MyoPro devices, marking a significant milestone for the company and its patients.

Myomo, Inc. has appointed Heather Getz to its Board of Directors, increasing the board size to seven members and naming her chair of the audit committee.

Myomo, a wearable medical robotics company, announced a record backlog and revenue growth in Q4 2023, fueled by the inclusion of Medicare Part B patients and increased demand for their MyoPro device.

Myomo, Inc. has received final Medicare fee schedule payment rates for its MyoPro devices, effective April 1, 2024.

Myomo, Inc. has amended employment agreements for its CFO and Chief Medical Officer, increasing base salary for the CFO and enhancing severance and change in control benefits for both executives.

Myomo, Inc. has announced a $6 million registered direct offering to scale operations for Medicare Part B patients, alongside preliminary Q4 revenue of $4.6 to $4.8 million and a backlog of 230 patients.